Current Recommendations on Optic Neuritis

Abstract

Background Optic neuritis is a special challenge to the ophthalmologist. It is a relatively frequent condition but difficult to seize morphologically. It has neurological implications and is subject matter of recent trials.

Methods Selective literature search including the authorsʼ professional experience.

Results Practical aids for the ophthalmological management of optic neuritis are derived from the best available evidence and the recent literature is discussed.

Conclusions The present paper provides evidence-based recommendations for a safe handling of optic neuritis as well as information on current issues.

Key words

neuroophthalmology - optic neuritis - guideline - steroids - neuromyelitis optica - chronic relapsing inflammatory optic neuropathy

Publication History

Received: 10 September 2020

Accepted: 30 September 2020

Article published online:
17 November 2020

• References/Literatur

• 1 Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014; 13: 83-99 doi:10.1016/S1474-4422(13)70259-X
• 2 Kurne A, Karabudak R, Yalcin-Cakmakli G. Recurrent optic neuritis: clues from a long-term follow up study of recurrent and bilateral optic neuritis patients. Eye Brain 2010; 2: 15-20
• 3 Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1649-1673 doi:10.1098/rstb.1999.0510
• 4 Schlossman A, Phillips CC. Optic neuritis in relation to demyelinating diseases; a clinical study. Am J Ophthalmol 1954; 37: 487-494 doi:10.1016/0002-9394(54)92198-4
• 5 Deutsche Ophthalmologische Gesellschaft e.V. (DOG). Optikusneuritis. Accessed September 6, 2020 at https://www.awmf.org/leitlinien/detail/ll/045-010.html
• 6 Anonymous The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthal 1991; 109: 1673-1678 doi:10.1001/archopht.1991.01080120057025
• 7 Beck RW, Cleary PA, Anderson MM. et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-588 doi:10.1056/NEJM199202273260901
• 8 Wilhelm H. Pupillenreaktionen – Pupillenstörungen. Stuttgart: Kohlhammer; 1991
• 9 Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. J Neuroophthalmol 2011; 31: 58-68 doi:10.1097/WNO.0b013e31820cf78a
• 10 Gaier ED, Boudreault K, Rizzo JF. et al. Atypical optic neuritis. Curr Neurol Neurosci Rep 2015; 15: 76 doi:10.1007/s11910-015-0598-1
• 11 Trebst C, Jarius S, Berthele A. et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1-16 doi:10.1007/s00415-013-7169-7
• 12 Kidd D, Burton B, Plant GT. et al. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003; 126: 276-284
• 13 Horwitz H, Friis T, Modvig S. et al. Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol 2014; 261: 98-105 doi:10.1007/s00415-013-7166-x
• 14 Trauzettel-Klosinski S, Diener HC, Fahle M. Vergleich des Flimmertests nach Aulhorn mit den visuell evozierten Potentialen in der Diagnostik der Neuritis nervi optici. Fortschr Ophthalmol 1990; 87: 171-177
• 15 Pihl-Jensen G, Schmidt MF, Frederiksen JL. Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: A review. Clin Neurophysiol 2017; 128: 1234-1245 doi:10.1016/j.clinph.2017.03.047
• 16 Deutsche Gesellschaft für Neurologie (DGN), Kompetenznetz Multiple Sklerose (KKNMS). DGN/KKNMS Leitlinie zur Diagnose und Therapie der Multiplen Sklerose. Online-Version, Stand: 13.08.2014. Accessed August 18, 2020 at: http://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2016/02/dgn-kknms_ms-ll_20140813.pdf
• 17 Neo WL, Chin DCW, Huang XY. Rhinogenous optic neuritis with full recovery of vision – The role of endoscopic optic nerve decompression and a review of literature. Am J Otolaryngol 2018; 39: 791-795 doi:10.1016/j.amjoto.2018.08.008
• 18 de Sèze J, Kremer L, Collongues N. Neuromyelitis optica spectrum disorder (NMOSD): A new concept. Rev Neurol (Paris) 2016; 172: 256-262 doi:10.1016/j.neurol.2016.03.003
• 19 Chun BY, Cestari DM. Myelin oligodendrocyte glycoprotein-IgG-associated optic neuritis. Curr Opin Ophthalmol 2018; 29: 508-513 doi:10.1097/ICU.0000000000000520
• 20 Kahloun R, Abroug N, Ksiaa I. et al. Infectious optic neuropathies: a clinical update. Eye Brain 2015; 7: 59-81 doi:10.2147/EB.S69173
• 21 Eggenberger ER. Infectious optic neuropathies. Continuum (Minneap Minn) 2019; 25: 1422-1437 doi:10.1212/CON.0000000000000777
• 22 Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2015; (08) CD001430 DOI: 10.1002/14651858.CD001430.pub4.
• 23 Cleary PA, Beck RW, Anderson MM. et al. Design, methods, and conduct of the optic neuritis treatment trial. Control Clin Trials 1993; 14: 123-142 doi:10.1016/0197-2456(93)90015-6
• 24 Petzold A, Braithwaite T, van Oosten BW. et al. Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry 2020; 91: 9-14 doi:10.1136/jnnp-2019-321653
• 25 Roed HG, Langkilde A, Sellebjerg F. et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810 doi:10.1212/01.WNL.0000152873.82631.B3
• 26 Raftopoulos R, Hickman SJ, Toosy A. et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 259-269 doi:10.1016/S1474-4422(16)00004-1
• 27 Tsakiri A, Kallenbach K, Fuglo D. et al. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012; 18: 72-81 doi:10.1177/1352458511415452
• 28 Gresle MM, Liu Y, Kilpatrick TJ. et al. Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. Mult Scler J Exp Transl Clin 2016; 2: 2055217316641704 doi:10.1177/2055217316641704
• 29 Esfahani MR, Harandi ZA, Movasat M. et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 863-869 doi:10.1007/s00417-011-1894-3
• 30 Suhs KW, Hein K, Sattler MB. et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199-210 doi:10.1002/ana.23573
• 31 Soltan Sanjari M, Pakdel F, Moosavi F. et al. Visual outcomes of adding erythropoietin to methylprednisolone for treatment of retrobulbar optic neuritis. J Ophthalmic Vis Res 2019; 14: 299-305 doi:10.18502/jovr.v14i3.4786
• 32 Diem R, Molnar F, Beisse F. et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open 2016; 6: e010956 doi:10.1136/bmjopen-2015-010956
• 33 Kezuka T, Ishikawa H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol 2018; 62: 101-108 doi:10.1007/s10384-018-0561-1
• 34 Beck RW, Cleary PA, Backlund JC. et al. The course of visual recovery after optic neuritis: Experience of the optic neuritis treatment trial. Ophthalmology 2020; 127(4S): S174-S181 doi:10.1016/j.ophtha.2020.01.027
• 35 Trapp BD, Peterson J, Ransohoff RM. et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285 doi:10.1056/NEJM199801293380502
• 36 Costello F, Coupland S, Hodge W. et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59: 963-969 doi:10.1002/ana.20851
• 37 Wilbur C, Reginald YA, Longoni G. et al. Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. Mult Scler Relat Disord 2019; 36: 101387 doi:10.1016/j.msard.2019.101387
• 38 Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727-732 doi:10.1001/archneur.65.6.727
• 39 Pihl-Jensen G, Wanscher B, Frederiksen JL. Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. Mult Scler 2020; DOI: 10.1177/1352458520917924.